What medication is contained in a transdermal motion‑sickness patch?

Motion Sickness Patch Medication

The transdermal motion sickness patch contains scopolamine, an anticholinergic medication that blocks acetylcholine receptors in the central nervous system to prevent motion sickness. 1, 2, 3

Active Ingredient and Formulation

• The commercially available transdermal scopolamine patch (TTS-S) contains a reservoir of 1.5 mg of scopolamine programmed to deliver 0.5 mg over a 3-day period 4
• A priming dose of 140 micrograms is incorporated into the adhesive layer to saturate skin binding sites and accelerate achievement of steady-state blood levels 4
• The patch releases scopolamine at a constant rate of approximately 5 micrograms per hour 4

Mechanism of Action

• Scopolamine works as an anticholinergic agent by blocking acetylcholine, a widespread CNS neurotransmitter, thereby reducing the neural mismatch that causes motion sickness 5
• The drug competitively inhibits muscarinic receptors for acetylcholine and acts as a nonselective muscarinic antagonist, producing central antiemetic effects 6

Application Timing and Effectiveness

• The patch should be applied to the postauricular area (behind the ear) at least 6-8 hours before the anti-motion sickness effect is required 5, 4
• The protective plasma concentration of scopolamine (estimated at 50 pg/mL) is attained after 6 hours, with steady state of approximately 100 pg/mL achieved 8-12 hours after application 4
• For faster protection when needed in less than 6 hours, the patch may be applied 1 hour before travel in combination with oral scopolamine 0.3 or 0.6 mg 4
• Transdermal scopolamine has been shown to reduce the incidence and severity of motion sickness by 60-80% compared to placebo 4

Comparative Efficacy

• Transdermal scopolamine was significantly more effective than oral cinnarizine (25 mg) in preventing seasickness among naval crew (P = 0.029) 7
• The patch was more effective than oral meclizine or cinnarizine, similar to oral scopolamine 0.6 mg or promethazine plus ephedrine, and the same as or superior to dimenhydrinate 4
• 41% of subjects preferred transdermal scopolamine versus only 12% who preferred cinnarizine (P < 0.001), citing higher efficacy, lower adverse reaction rates, and convenience 7

Common Adverse Effects

• Dry mouth occurs in approximately 50-60% of users, drowsiness in up to 20%, and allergic contact dermatitis in 10% 4
• Visual disturbances (blurred vision, difficulty with accommodation) are the most concerning side effect, occurring more frequently than with placebo 8, 4
• Transient impairment of ocular accommodation can occur, sometimes from finger-to-eye contamination after handling the patch 4
• The patch produces about half the incidence of drowsiness caused by oral dimenhydrinate or cinnarizine 4

Critical Safety Considerations

Elderly Patients

• Anticholinergic medications are an independent risk factor for falls in elderly patients; scopolamine should be initiated at reduced doses with close monitoring 5
• Toxic psychosis and confusion have been reported occasionally, mainly in elderly and pediatric patients 4
• Prescribing multiple anticholinergic agents concurrently should be avoided because cumulative anticholinergic burden markedly increases fall risk 5

Absolute Contraindications

• Scopolamine should be omitted entirely in individuals with glaucoma, urinary retention, or severe prostatic hypertrophy due to risk of exacerbating these conditions 5
• The drug is contraindicated in patients with known hypersensitivity to scopolamine or other belladonna alkaloids 6

Special Populations

• Scopolamine readily crosses the placenta and should be avoided in pregnancy unless expected therapeutic benefit clearly outweighs potential fetal risks 5
• The drug passes into breast milk; consideration should be given to interrupting breastfeeding or selecting alternative medication 5

Important Clinical Pitfalls

• The onset of benefit for transdermal scopolamine patches is approximately 12 hours, making them inappropriate for imminently needed relief 1
• After 72 hours, the patch should be removed and a new one applied behind the opposite ear 4
• 20-30% of subjects fail to attain the estimated protective plasma concentration, which may explain some treatment failures 4
• Concomitant use of over-the-counter medications with anticholinergic properties (decongestants, cold/flu remedies, allergy medications, sleep aids) can compound side effects 5
• Long-term use of vestibular suppressant medications like scopolamine can interfere with natural vestibular compensation and should not be used for chronic vestibular conditions 5